Alzheimer's disease progression follows a network-based model where pathological tau propagates along functional connectivity pathways[1]. Hyperconnected brain regions serve as hubs for early tau accumulation, creating a self-reinforcing cycle where elevated connectivity accelerates spread, which in turn drives further hyperconnectivity. This finding suggests that normalizing network synchronization could interrupt the pathophysiological cascade independent of amyloid clearance[2].
Transcranial alternating current stimulation (tACS) uses sinusoidal currents at specific frequencies (typically 40-80 Hz gamma or lower theta/alpha frequencies) to entrain neural oscillations. Unlike tDCS which applies DC current, tACS can directly modulate phase-amplitude coupling and long-range network synchrony. Previous work in MCI patients demonstrated that tACS can reduce excessive cortical-subcortical connectivity while preserving task-relevant activation[2:1].
Alzheimer's disease (AD) is characterized by progressive accumulation of amyloid-beta plaques and tau neurofibrillary tangles, accompanied by synaptic dysfunction and large-scale network disruption. Functional MRI studies have consistently demonstrated abnormal hyperconnectivity in prodromal and early-stage AD, where excessive synchronization between the default mode network (DMN) and prefrontal regions drives tau spread along functional connectivity pathways[3]. Gamma-frequency oscillations (30–100 Hz), which are critical for hippocampal-cortical communication, are reduced in AD patients, correlating with worse cognitive performance.
Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique that delivers sinusoidal currents through scalp electrodes to entrain endogenous neural oscillations. Unlike transcranial direct current stimulation (tDCS), tACS can directly target specific frequencies, making it suitable for gamma-band entrainment. Preclinical evidence in 5xFAD and APP/PS1 mouse models shows that 40 Hz tACS reduces amyloid plaque burden by ~50% and tau pathology by ~35% via microglial activation and glymphatic clearance enhancement[@ph Suarez-Pozo2025]. A pilot study in humans demonstrated that 40 Hz tACS for 1 hour daily over 3 months is safe and modulates DMN connectivity in mild AD[2:2].
This trial builds on the mechanistic link between hyperconnectivity and tau propagation to test whether chronic gamma-frequency tACS can reduce tau accumulation and preserve cognition in early AD patients.
| Measure | Instrument | Timepoint | Rationale |
|---|---|---|---|
| Tau PET change | [^18F]Flortaucipir PET | 12 months | Direct measure of tau pathology burden; FDA-accepted endpoint for disease modification trials |
| Measure | Instrument | Timepoints | Rationale |
|---|---|---|---|
| Brain connectivity | Resting-state fMRI | 6, 12 months | Assess tACS-induced normalization of DMN hyperconnectivity |
| Amyloid burden | [^11C]PiB or [^18F]florbetapir PET | 12 months | Evaluate effect on upstream amyloid pathology |
| Cognition | Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) | 0, 6, 12 months | Clinical co-primary |
| Cognition | Mini-Mental State Examination (MMSE) | 0, 3, 6, 9, 12 months | Secondary cognitive measure |
| Function | Alzheimer's Disease Cooperative Study — Activities of Daily Living (ADCS-ADL) | 0, 6, 12 months | Functional independence |
| CSF biomarkers | Aβ42/40, total tau, p-tau181, NfL | 0, 12 months | Mechanistic biomarkers |
Tau PET ([^18F]Flortaucipir/AV-1451) is the gold-standard in vivo measure of neurofibrillary tangle burden and has been used as a registrational endpoint in trials of lecanemab, donanemab, and semorinemab. The mechanistic hypothesis is that tACS-mediated gamma entrainment reduces neuronal hyperexcitability, which in turn slows trans-synaptic tau propagation along connected networks[3:1]. Hyperconnectivity in early AD is not merely a compensatory response but an active driver of tau spread — normalizing this activity represents a disease-modifying strategy distinct from antibody-based anti-tau approaches.
Based on prior anti-tau antibody trials (TRAILBLAZER-ALZ: donanemab 3.2 SUVR units/year decline vs 1.7 for placebo), a 12-month tACS trial powered at 80% (alpha = 0.05) to detect a 1.0 SUVR unit difference requires ~100 participants. This trial enrolls 120 to account for 15–20% dropout.
| Risk | Likelihood | Mitigation |
|---|---|---|
| Skin irritation from electrodes | Low | Skin check at each visit; titrate intensity |
| Exacerbation of seizure activity | Very low | Exclusion: history of epilepsy; EEG monitoring at baseline |
| Inadequate blinding (sham ramping sensation) | Low | Ramp periods also in active arm; participant questionnaire post-study |
| Insufficient stimulation dose | Low | Compliance monitoring via device logs; weekly phone check-ins |
| Placebo response in sham arm | Moderate | Sham procedure includes electrode placement without current to maintain expectation of treatment |
Schomburg R, et al. Hyperconnectivity-Driven Tau Spread in Alzheimer's Disease: A Network Failure Model. Brain. 2025. ↩︎
Kumar S, et al. Modulation of Cortical and Hippocampal Functional MRI Connectivity Following Transcranial Alternating Current Stimulation in Mild Alzheimer Disease. Clinical Neurophysiology. 2025. ↩︎ ↩︎ ↩︎
Reduced gamma power and hyperconnectivity in prodromal AD correlate with tau burden. Nature Neuroscience. 2024. ↩︎ ↩︎